Case Profile of Anemia Associated with Myelodysplastic Syndrome (MDS) Treated with Darbepoetin alfa - Dr. Rishu Vidhatri - Video
Overview
This case discusses a 62-year-old male diagnosed with Myelodysplastic Syndrome (MDS) presenting with severe anemia and transfusion dependence. Despite regular transfusions, the patient continued to experience fatigue and dyspnea, significantly impacting quality of life.
With a serum erythropoietin level <750 mIU/mL, treatment with darbepoetin alfa was initiated, leading to a clinically meaningful hemoglobin rise from 5.6 g/dL to 9 g/dL and notable symptomatic improvement.
This case highlights the importance of early ESA therapy, patient selection based on EPO levels, and targeted management in intermediate-risk MDS to reduce transfusion burden and improve outcomes.
Watch to understand:
• When to initiate ESA in MDS
• Role of darbepoetin alfa in anemia management
• Practical insights for improving patient quality of life
Speakers
